An undercover report by the UK's Sunday Times newspaper has revealed that a Chinese factory is allegedly producing counterfeit Viagra (sildenafil citrate) tablets with three times the permitted dose. Undercover reporters posing as representatives of a UK-based prescription drug wholesale firm were even offered large quantities of cardiovascular and oncological products.
The report claims that Gabriel Zhang, a Tianjin-based businessman, offered to manufacture 200,000 packages per month of three drugs: the antiplatelet agent Plavix (clopidogrel), which is co-marketed in the UK by France's Sanofi-Aventis and the USA-based Bristol-Myers Squibb, Anglo-Swedish drug major AztraZeneca's oncology product Casodex (bacalutamide); and US firm Eli Lilly's schizophrenia drug Zyprexa (olanzapine). All three drugs were the subject of product recalls ordered by the UK's Medicines and Healthcare products Regulatory Authority (MHRA; Marketletter June 11), after fake batches were found entering the country.
"Viagra" had excess active ingredient
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze